Phase 3 trial of once-weekly canvuparatide remains on track to initiate in Q3 2026 following recently completed, successful End-of-Phase 2 ...

(Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today ...

Dick's Sporting Goods traded higher in early action on Thursday after beating estimates with its Q4 earnings report and ...

Sleep Number Corporation (Nasdaq: SNBR) today reported results for fourth quarter and the year ended January 3, 2026.

Revenue from continuing operations of $151.2 million, an increase of 5.2% compared to $143.7 million for the quarter ended December 31, 2024. Pro forma revenue increased approximately 4.6% compared to ...

Ergatta's 2026 Revenue Expected to Exceed $10 Million with Approximately 30% EBITDA MarginTRNR received $6.4 Million on ...

Thank you for standing by, and welcome to EverCommerce's Fourth Quarter 2025 Earnings Call. My name is Josh, and I will be your operator for today. [Operator Instructions] As a reminder, this ...

Two, executing in record speed for Sleep Number on a completely new line of products that Linda described, which we are launching on March 23; and three, modernizing our marketing engine with new ...

Consolidated Operating Income -- $800,000, down from $1,500,000, with $400,000 in M&A due diligence expenses included. Net Operating Loss Carryforwards -- $18,900,000 expired, with $15,500,000 ...

Sonida Senior Living, Inc. (NYSE:SNDA) Q4 2025 Earnings Call Transcript March 11, 2026 Sonida Senior Living, Inc. misses on earnings expectations. Reported EPS is $-1.72236 EPS, expectations were $-1.

EET | Gofore Oyj | Other information disclosed according to the rules of the Exchange Gofore Oyj Other information disclosed according to stock exchange rules 12 March 2026 at 10:00 ...

With its $1.8B merger with CNL now complete, Sonida plans to sell 10% of the communities in the combined portfolio, CEO Brandon Ribar said.